TheraRadar
← Back
Data updated: Jun 28, 2026

AR HOLDING CO INC

Pharma
Pharmaceuticals

AR HOLDING CO INC is a pharmaceutical company with 1 FDA-approved products.

2009
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jul 23, 2026 — Rivoceranib + camrelizumab
12d
Jul 23, 2026 — Rivoceranib + camrelizumab
Aug 10, 2026 — Oveporexton (TAK-861)
+2 more dates (Pro)

AR HOLDING CO INC's Key Drugs

AR HOLDING CO INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AR HOLDING CO INC's Recent FDA Approvals

New NDA/BLA approvals for AR HOLDING CO INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AR HOLDING CO INC's Therapeutic Areas

Disease areas where AR HOLDING CO INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AR HOLDING CO INC Pipeline Snapshot

Active clinical trials for AR HOLDING CO INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling